


Pharmaceuticals & Biotechnology | Small Cap
Syncom Formulations exhibits a mixed financial profile. The company demonstrates strong solvency and growth, indicating a solid financial foundation and promising expansion. Profitability is also a notable strength, driven by healthy margins and returns on capital. However, efficiency and financial metrics suggest areas needing attention. While liquidity is adequate, there's room to optimize cash management. The company's revenue, operating profit, and EPS are growing significantly. Syncom Formulations maintains a strong position with zero debt. While fixed asset and capital turnover are low, inventory management is efficient. The company shows potential for continued growth and profitability, but improvements in operational efficiency and financial management are crucial for sustained success.
Syncom Formulations exhibits a mixed financial profile. The company demonstrates strong solvency and growth, indicating a solid financial foundation and promising expansion. Profitability is also a notable strength, driven by healthy margins and returns on capital. However, efficiency and financial metrics suggest areas needing attention. While liquidity is adequate, there's room to optimize cash management. The company's revenue, operating profit, and EPS are growing significantly. Syncom Formulations maintains a strong position with zero debt. While fixed asset and capital turnover are low, inventory management is efficient. The company shows potential for continued growth and profitability, but improvements in operational efficiency and financial management are crucial for sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
16.27
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
16.27
P/B RATIO
2.99
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
2.48
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.34
EV/EBITDA RATIO
11.07
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹13.18 as on Aug 6, 2026.
The company exhibits excellent growth across all measured metrics. This signals a strong upward trajectory in its business operations and financial performance. The company's revenue, operating profit, and EPS are growing significantly. Such robust growth is a positive indicator of the company's competitive positioning and ability to capitalize on market opportunities. Maintaining this growth momentum is crucial for long-term success.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 2.78 | 18.02 | 76.72 | 5.62 | |
| Operating Profit Growth Rate | 0 | 50 | 80 | 42.59 | |
| Earnings Per Share (EPS) Growth | -8.7 | 28.57 | 96.3 | 52.83 | |
| Asset Growth Rate | 22.73 | 7.14 | 1.98 | 29.3 | |
| Net Income Growth Rate | 0 | 25 | 96 | 55.1 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.02 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 44.01 | Overvalued | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 16.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 67.13 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 37.59 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.82 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 47.48 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 29.43 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral